Perspective Therapeutics (NYSE:CATX) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Perspective Therapeutics (NYSE:CATX) in a report published on Friday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

A number of other equities research analysts have also recently weighed in on CATX. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Saturday, July 12th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Thursday. Finally, B. Riley restated a “buy” rating and issued a $12.00 price target (up previously from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and a consensus target price of $12.56.

Perspective Therapeutics Price Performance

CATX stock opened at $3.64 on Friday. The company’s 50-day moving average price is $3.53 and its 200 day moving average price is $3.08. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $13.56.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ground Swell Capital LLC purchased a new stake in shares of Perspective Therapeutics during the second quarter worth about $56,000. Los Angeles Capital Management LLC acquired a new stake in Perspective Therapeutics during the second quarter worth approximately $61,000. MetLife Investment Management LLC boosted its position in Perspective Therapeutics by 40.9% during the first quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock worth $67,000 after acquiring an additional 9,082 shares during the last quarter. Citizens Financial Group Inc. RI grew its stake in Perspective Therapeutics by 100.0% in the 1st quarter. Citizens Financial Group Inc. RI now owns 100,000 shares of the company’s stock worth $213,000 after acquiring an additional 50,000 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Perspective Therapeutics by 19.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock valued at $224,000 after acquiring an additional 11,472 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.